Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2000
06/06/2000US6071929 Selective blockers of n-methyl-d-aspartic acid for teatment of nervous system and brain disorders or injuries
06/06/2000US6071927 Tachykinnin antagonists for the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia
06/06/2000US6071925 Antidepressants, anticonvulsants or antianxiety agents, also for treatment of memory loss in alzheimer's disease
06/06/2000US6071921 4-phenyl-7-arylquinoazolines; angiogenisis inhibitors and/or vascular permeability reducing effects in warm-blooded animals; anticarcinogenic and -arthritic agents; rheumatic diseases; vascular endothelium growth factor inhibitors
06/06/2000US6071920 Bind to 5ht 1a receptors for treating disorders of the lower urinary tract; cns disorders; anxiolytic agents; antidepressants; hypotensive agents; sleep and eating disorders
06/06/2000US6071919 Stimulate the immunological system and to induce the production of hypercellular bone marrow and extramedullary hematopoiesis; antitumor and -carcinogenic agents; autoimmune diseases; viricides; hepatitis
06/06/2000US6071906 Inhibits or modulates the inducible isoform of nitric oxide synthase over the the constitutive isoforms; antiarthritic, -diabetic, ischemic, thrombosis agents; cardiovascular disorders; toxic shock syndrome; autoimmune diseases
06/06/2000US6071899 Azetidinone derivatives for the treatment of atherosclerosis
06/06/2000US6071894 Sensor histidine kinase of Staphylococcus aureus
06/06/2000US6071890 Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
06/06/2000US6071722 Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1)
06/06/2000US6071720 Polynucleotide coding a polypeptide associated with ionic mobility; for the diagnosis, treatment or prevention of nervous system disorders, cardiovascular disorders and cancer; anticarcinogenic agents
06/06/2000US6071701 Detecting polynucleotide sequences which code polypeptide associated with inflammation; contacting nucleic acids with a polynucleotide sequence which codes inflammation polypeptide, allowing hybridization, detecting hybridization products
06/06/2000US6071523 Oral administering from squeezable container; storage stability, heat resistance; drug delivery
06/06/2000US6071516 Administering normal gamma-globulin
06/06/2000US6071509 Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
06/06/2000CA2206233C Combination dosage form comprising cetirizine and pseudoephedrine
06/06/2000CA2198599C Salts of an anti-migraine indole derivative
06/06/2000CA2145541C Cosmetic composition containing retinol
06/06/2000CA2114830C Lactone compound and process of production thereof
06/04/2000CA2291471A1 Lowering blood levels of lipoprotein(a)
06/02/2000WO2000031548A1 Prevention and treatment of amyloid-associated disorders
06/02/2000WO2000031291A1 Method for screening for substances which are activators, inhibitors or binders of pkb by the use of a substrate peptide and the use of the substrate peptide
06/02/2000WO2000031286A1 Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
06/02/2000WO2000031263A2 Gtpase associated proteins
06/02/2000WO2000031248A1 Humanized monoclonal antibodies
06/02/2000WO2000031247A2 Recombinant methods and materials for producing epothilone and epothilone derivatives
06/02/2000WO2000031244A1 Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof
06/02/2000WO2000031242A2 Engineered cytotoxic ribonuclease
06/02/2000WO2000031238A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
06/02/2000WO2000031137A1 Amino-terminal modified parathyroid hormone (pth) analogs
06/02/2000WO2000031135A1 TGF$G(b)1 INHIBITOR PEPTIDES
06/02/2000WO2000031133A2 Potassium channel interactors and uses therefor
06/02/2000WO2000031129A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
06/02/2000WO2000031124A2 Peptides that modulate the interaction of b class ephrins and pdz domains
06/02/2000WO2000031120A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000WO2000031109A1 USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION
06/02/2000WO2000031100A2 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/02/2000WO2000031095A2 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
06/02/2000WO2000031094A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
06/02/2000WO2000031093A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
06/02/2000WO2000031092A2 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
06/02/2000WO2000031078A1 1-acylazetidine derivatives
06/02/2000WO2000031070A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same
06/02/2000WO2000031068A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants
06/02/2000WO2000031067A1 Propanoic acid derivatives as integrin inhibitors
06/02/2000WO2000031063A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
06/02/2000WO2000031061A1 2-oxoimidazole derivatives
06/02/2000WO2000031060A1 Scavenger compounds
06/02/2000WO2000031053A1 Il-5 inhibiting 6-azauracil derivatives
06/02/2000WO2000031051A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000WO2000031050A1 Quinoline and quinoxaline compounds
06/02/2000WO2000031049A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000WO2000031048A1 N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
06/02/2000WO2000031046A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them
06/02/2000WO2000031039A1 Substituted benzo[de]isoquinoline-1,3-diones
06/02/2000WO2000031038A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands
06/02/2000WO2000031037A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000WO2000031033A1 Piperidine ccr-3 receptor antagonists
06/02/2000WO2000031032A1 Pyrrolidine derivatives-ccr-3 receptor antagonists
06/02/2000WO2000030668A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
06/02/2000WO2000030635A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000WO2000030588A2 Treatment of hypertension
06/02/2000WO2000030446A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000WO2000013703A9 Methods of treating hypertension and compositions for use therein
06/02/2000WO2000012119A3 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa
06/02/2000WO2000008177A3 Death associated kinase containing ankyrin repeats (dakar)
06/02/2000WO1999066075A3 Diagnostic method based on quantification of extramitochondrial dna
06/02/2000WO1999061097A9 Alpha emitting constructs and uses thereof
06/02/2000CA2352584A1 Quinoline and quinoxaline compounds
06/02/2000CA2352583A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000CA2352493A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
06/02/2000CA2352486A1 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
06/02/2000CA2352477A1 Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof
06/02/2000CA2352316A1 Treatment of hypertension
06/02/2000CA2352261A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000CA2352144A1 Scavenger compounds
06/02/2000CA2352043A1 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
06/02/2000CA2351893A1 Peptides that modulate the interaction of b class ephrins and pdz domains
06/02/2000CA2351865A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000CA2351725A1 Substituted pyrazoles as p38 kinase inhibitors
06/02/2000CA2351631A1 Piperidine quaternary salts-ccr-3 receptor antagonists
06/02/2000CA2351365A1 Potassium channel interactors and uses therefor
06/02/2000CA2351361A1 Gtpase associated proteins
06/02/2000CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000CA2351348A1 Substituted benzo[de]isoquinoline-1,3-diones
06/02/2000CA2351347A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000CA2351166A1 Method for screening for substances which are activators, inhibitors or binders of pkb by the use of a substrate peptide and the use of the substrate peptide
06/02/2000CA2351061A1 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350903A1 Pyrrolidine derivatives-ccr-3 receptor antagonists
06/02/2000CA2350759A1 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350758A1 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350755A1 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350753A1 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350189A1 Recombinant methods and materials for producing epothilone and epothilone derivatives
06/02/2000CA2349721A1 N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases
06/02/2000CA2349555A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000CA2349229A1 Prevention and treatment of amyloid-associated disorders
06/02/2000CA2347940A1 Use of core 2 glcnac transferase inhibitors in treating inflammation
05/2000
05/31/2000EP1004598A2 Coated carrier materials for the purification of blood, plasma and tissues, and columns comprising said carrier materials
1 ... 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 ... 1564